RCM
REGN icon

Riverhead Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Riverhead Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$986K Sell
3,556
-236
-6% -$69.8K 0.04% 492
2019
Q2 		$1.19M Sell
3,792
-2,555
-40% -$851K 0.04% 445
2019
Q1 		$2.61M Buy
6,347
+4,185
+194% +$1.72M 0.11% 260
2018
Q4 		$808K Buy
2,162
+412
+24% +$151K 0.04% 503
2018
Q3 		$707K Buy
1,750
+450
+35% +$171K 0.03% 603
2018
Q2 		$448K Buy
1,300
+80
+7% +$25K 0.02% 717
2018
Q1 		$420K Sell
1,220
-186
-13% -$64.7K 0.02% 727
2017
Q4 		$529K Buy
1,406
+650
+86% +$263K 0.02% 639
2017
Q3 		$338K Hold
756
– – 0.02% 751
2017
Q2 		$371K Sell
756
-129
-15% -$56.5K 0.02% 696
2017
Q1 		$343K Buy
885
+229
+35% +$84.9K 0.02% 628
2016
Q4 		$241K Sell
656
-100
-13% -$38K 0.01% 684
2016
Q3 		$304K Sell
756
-1,400
-65% -$562K 0.02% 588
2016
Q2 		$119K Sell
2,156
-14,375
-87% -$5.54M ﹤0.01% 1111
2016
Q1 		$5.96M Buy
16,531
+7,255
+78% +$2.99M 0.08% 288
2015
Q4 		$5.04M Sell
9,276
-112
-1% -$60.7K 0.07% 328
2015
Q3 		$4.37M Sell
9,388
-450
-5% -$242K 0.07% 326
2015
Q2 		$5.02M Sell
9,838
-498
-5% -$243K 0.08% 319
2015
Q1 		$4.67M Sell
10,336
-42
-0.4% -$17.8K 0.07% 320
2014
Q4 		$4.26M Sell
10,378
-91
-0.9% -$35.8K 0.06% 329
2014
Q3 		$3.77M Buy
10,469
+325
+3% +$109K 0.06% 336
2014
Q2 		$2.86M Buy
10,144
+2,126
+27% +$630K 0.05% 368
2014
Q1 		$2.41M Buy
8,018
+113
+1% +$34.8K 0.05% 365
2013
Q4 		$2.17M Buy
+7,905
New +$2.27M 0.06% 330

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Riverhead Capital Management's REGN Position: Q3 2019 in Review

Riverhead Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 6.2% in Q3 2019, selling an estimated $69.8K and leaving 3,556 shares worth $986K. The position accounts for 0.04% of the portfolio, ranked #492.

Riverhead Capital Management first reported a position in REGN in Q4 2013 and has held it in 24 quarters since. The position peaked at $5.96M in Q1 2016. 633 funds tracked by Wall St. Rank hold REGN as of Q3 2019.

  • Riverhead Capital Management held 3,556 shares of Regeneron Pharmaceuticals worth $986K as of Q3 2019.
  • Riverhead Capital Management sold 236 Regeneron Pharmaceuticals shares in Q3 2019, an estimated $69.8K.
  • Regeneron Pharmaceuticals made up 0.04% of Riverhead Capital Management's portfolio in Q3 2019, its #492 holding.
  • Riverhead Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2013 and has held it in 24 quarters since.
  • Riverhead Capital Management's Regeneron Pharmaceuticals position peaked at $5.96M in Q1 2016.
  • 633 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.